Regulation of cellular functions and diseases by the MARCH E3 ubiquitin ligases Authors: Qi Zhang, Yu-Ting Qiao, Shu Li Published: 2026 ABSTRACT AbstractThe membrane-associated RING-CH (MARCH) family is a type of membrane-localized E3 ubiquitin ligase, which catalyze substrate ubiquitination via their characteristic RING-CH domains. MARCH proteins target their substrates for polyubiquitination of different linkage types and degradation via distinct routes. This review outlines recent advancements about the structural features, subcellular localizations, expression profiles of MARCH proteins and their roles in regulation of physiological processes and diseases, such as immune response, organelle homeostasis and tumorigenesis. Future studies would identify additional targets of the MARCH family and reveal the regulatory networks of MARCH family on substrates, offering an opportunity to target the MARCH family for development of drugs against severe human diseases.Keywords: MARCH, E3 ligase, Ubiquitination, Immune regulation, Diseases Introduction Ubiquitination, a prevalent post-translational modification, is crucial for regulating substrate stability, localization, and protein-protein interactions. The ubiquitination process relies on coordinated actions of three types of enzymes: E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and E3 ubiquitin ligase, which leads to the eventual conjugation of mono-ubiquitin or polyubiquitin moieties to a substrate protein (Ablack et al., 2015). E3 ubiquitin ligases are extensively studied due to their roles in determining substrate specificity. They are categorized into four primary types based on their structural features, including RING-type, HECT-type, RBR-type and U-box type (Yang et al., 2021) (Fig. 1). The RING E3 ubiquitin ligase serves as a scaffold, positioning the E2 enzyme near the substrate and facilitating the transfer of ubiquitin to the substrate, whereas the HECT E3 ubiquitin ligase can directly transfer ubiquitin onto the substrate (Rotin and Kumar, 2009). The RBR-type E3 ligase, in contrast, incorporates features from both the RING and HECT families, functioning like a RING-type enzyme in the initial step but subsequently forming a thioester intermediate, akin to a HECT-type ligase (Sokolova and Naumann, 2021). The U-box E3 ligases are structurally similar to RING-type ubiquitin ligases, but unlike typical RING domains, the U-box lacks bound Zn2+ ions (Pruneda et al., 2012). The U-box domain mediates engagement with ubiquitin-loaded E2 enzymes and facilitates the direct transfer of ubiquitin from E2 to specific lysine residues in substrate proteins (Hatakeyama et al., 2001). The classification of E3 ligases. E3 ligases are classified into four main types based on their structural and biochemical characteristics: (A) In HECT type E3 ligases, the C-terminal HECT domain is conserved, and the N-terminus contains different domains according to the specific subtype. HECT type E3 ligases participate in the ubiquitination process through a two-step reaction: initially, ubiquitin is carried by E2 ligase to the HECT domain, and then it is transferred to a catalytic cysteine on the E3 ligase. (B) RING type E3 ligases are defined by a zinc-binding domain known as RING located at the N-terminus, which facilitates the direct transfer of ubiquitin from E2 ligase to the substrate. (C) U-box type E3 ligases have a U-box domain at the C-terminus that binds to ubiquitin-charged E2 ligase and promotes ubiquitin transfer. (D) The RBR type E3 ligases are composed of two predicted RING domains, RING1 and RING2, with an IBR domain in between. The process of ubiquitination catalyzed by RBR E3 ligases involves two stages: first, ubiquitin is transferred to the E3's catalytic RING2 domain, and then to the substrate. The MARCH proteins belong to the RING finger type E3 ligases. MARCH proteins are a subgroup of RING-type E3 ubiquitin ligases. Most of the MARCH proteins are located either on the plasma membrane or on organellar membranes. MARCH proteins were initially identified as the mammalian structural equivalents of the viral immunosuppressive membrane ubiquitin ligases K3 and K5, which are derived from Kaposi's sarcoma-associated herpesvirus (KSHV) (Lehner et al., 2005; Singh et al., 2024). The first cellular MARCH protein to be recognized is c-MIR (currently referred to as MARCH8), which was discovered through BLAST searches of the human genome databases (Goto et al., 2003). To date, eleven MARCH family members have been characterized in mammals. Nine of them possess a typical configuration comprising an N-terminal RING-CH domain and several transmembrane domains. Two of the MARCH proteins, including MARCH7 and MARCH10, have a RING-CH motif at their C-terminus and do not contain a transmembrane domain. Therefore, these two MARCH proteins are atypical MARCH family members (Zheng, 2021). Studies in the past years have revealed roles of MARCH family proteins in a variety of physiological and pathological processes, including immune regulation (Feng et al., 2022; Zeng et al., 2022), mitochondrial homeostasis (Vringer et al., 2024), autophagy (Shi et al., 2023), tumorigenesis (Behera et al., 2024), and antiviral immunity (Zhang et al., 2025). This review aims to offer a comprehensive summary on the structures, expression profiles, subcellular localizations, and substrates of MARCH proteins as well as their regulation of cellular processes and diseases. Structures of MARCH proteins The most distinctive structural feature of MARCH proteins is their unique RING-CH domain and the transmembrane domains. Unlike the canonical RING-CH with a C3HC4-type domain, the RING-CH domain of MARCH proteins adopts a C4HC3-type zinc finger motif, with differences primarily reflected in the identity of the fourth and fifth metal-coordinating residues, as well as in the length of the peptide segment connecting the two zinc-binding sites (Samji et al., 2014). This structural configuration, together with their membrane localization for the typical MARCH proteins, endows them with distinct substrate recognition and catalytic activities, enabling them to selectively ubiquitinate specific membrane proteins, such as immune receptors (Jabbour et al., 2009), viral glycoproteins (Tada et al., 2015), and themselves (Bourgeois-Daigneault and Thibodeau, 2012). With the exceptions of the atypical MARCH7 and MARCH10, the majority of mammalian MARCH proteins possess an N-terminal RING-CH domain and a minimum of two transmembrane domains (Fig. 2). MARCH7 and MARCH10 lack identifiable transmembrane regions, and their RING-CH domains are situated at the C-terminus (Samji et al., 2014). Consequently, MARCH7 and MARCH10 are two atypical members of the MARCH family. Phylogenetic analysis indicates that transmembrane-containing MARCH proteins are categorized into several sub-groups, including MARCH1/8, MARCH2/3, and MARCH4/9/11, with MARCH5 and MARCH6 separated from the other subgroups. Recent work has demonstrated that the transmembrane domains of MARCH proteins are essential for them to recognize substrates, most of which are membrane proteins (Lin et al., 2019). Schematic presentation of MARCH proteins. The domain organization and subfamily classification for MARCH family members is shown. RING-CH, RING-CH finger domain; TM, transmembrane domain; PDZ, PDZ-binding motif; Pro rich, proline rich domain; Ser rich, serine rich motif; Tyr-based motif, tyrosine-based motif; Poly-Ser motif, poly-serine motif. The phylogenetic tree of MARCH proteins was generated with Clustal Omega alignment using the protein sequences in the Uniprot database. Some MARCH family members have more than just the conserved RING-CH domains and transmembrane regions. They also carry other types of functional domains, which serve important auxiliary roles, such as regulation of subcellular localization, protein-protein interactions and substrate recognition (Lin et al., 2019). Among these domains, C-terminal PDZ-binding motifs have been more extensively studied. MARCH2, MARCH3, and MARCH11 all possess a conserved PDZ binding motif at their C-terminal region, which allows them to specifically interact with adaptor proteins containing PDZ domains, such as Veli3 (Nakamura et al., 2005). It has been shown that the MARCH11 mutant lacking the PDZ binding motif loses its ability to bind its substrate Veli3 (Morokuma et al., 2007). It has also been shown that MARCH2 and MARCH3 rely on their PDZ binding motifs for their proper localization and function in the cell (Lin et al., 2019). For example, a study showed that MARCH2 binds directly to PGAM5 via its transmembrane domains and PDZ-binding motif, thus promoting the development of myocardial ischemia-reperfusion injury (Liu et al., 2024b). A study has also demonstrated that deletion of the PDZ-binding motif in MARCH2 disrupts its localization to cell–cell contact sites (Cao et al., 2008), highlighting the importance of the PDZ binding motifs in MARCH proteins. In addition to PDZ binding motifs, the tyrosine-based YXXΦ motifs (where X can be any amino acid and Φ denotes any hydrophobic residues) in MARCH8 participate in clathrin-mediated endocytosis (Kaksonen and Roux, 2018; Zhang et al., 2020). The N-terminal proline-rich motif in MARCH4, 9, and 11 facilitates interactions between these MARCH proteins and their binding partners or substrates (Lin et al., 2019). MARCH7 features a disordered serine-rich region at its N-terminus, which is highly similar in sequence to serine/arginine-rich (SR) proteins and contains motifs for RNA recognition. MARCH7 is located at nuclear speckles, which are key to pre-mRNA processing and mRNA export, suggesting MARCH7 might participate in these processes (Flach et al., 2014; Nathan et al., 2008). Subcellular localizations of MARCH proteins MARCH proteins are distributed across various cellular compartments, including lysosomes, endosomes, Golgi apparatus, endoplasmic reticulum (ER), cytosol and plasma membrane. The functions of MARCH proteins are directly regulated by their localizations. MARCH1, MARCH2, MARCH3, MARCH8, and MARCH9 are primarily localized to the endosomal/lysosomal system and the plasma membrane (Lin et al., 2019). Among them, MARCH1 localizes to endosomal and lysosomal membranes and also recycles to the cell surface. By mediating ubiquitination of lysine residues within the cytoplasmic tail of MHC class II molecules, it retains MHC class II molecules in endosomal compartments, thereby limiting their presence on the plasma membrane (Kim et al., 2021). MARCH8 has a localization and distribution highly similar to MARCH1 (Villalón-Letelier et al., 2022). It has been shown that MARCH8 is involved in the development of thymic epithelial cells (TECs) (Liu et al., 2016) and alveolar epithelial cells (AECs) (Schriek et al., 2021). MARCH2 and MARCH3 are found in endosomes, ER and lysosomes (Fukuda et al., 2006; Nakamura et al., 2005). MARCH3 has been shown to be also enriched in early endosomes and regulate signaling mediated by the interleukin-1 (IL-1) receptor complex (Lin et al., 2018). MARCH9 is localized to the Golgi apparatus and lysosomes to regulate the homeostasis of ICAM-1 and MHC class I molecules (De Angelis Rigotti et al., 2017; Shen et al., 2018). MARCH4 is mostly found in the Golgi apparatus, where it reduces levels of MHC class I molecules through ubiquitination (Bartee et al., 2004). It has also been shown that MARCH4 can target substrates while they are moving from the ER to the Golgi apparatus (Bartee et al., 2004). MARCH6 is a ubiquitin ligase that resides in the ER and participates in ER-associated degradation (Mehrtash & Hochstrasser, 2022; Schmidt et al., 2020; Stefanovic-Barrett et al., 2018). MARCH11 has been shown to play a certain role in spermatogenesis (Yogo et al., 2012). MARCH5 is unique within the MARCH family for its localization to mitochondria. MARCH5 sits on the outer membrane of mitochondria with its N-terminal RING-CH domain oriented towards the cytosol, which allows it to interact with cytoplasmic E2 enzymes and various substrate proteins (Yonashiro et al., 2006). It has been demonstrated that MARCH5 is crucial for preserving the morphology of mitochondria, regulating mitophagy, and formation of mitochondria-derived vesicles (Park et al., 2014; Shiiba et al., 2021; Sugiura et al., 2013; Tokuyama et al., 2022; Zheng et al., 2025). Without transmembrane domains, the atypical MARCH family members, MARCH7 and MARCH10, are mostly located in the cytosol and partially in the nucleus. MARCH7 has important functions in T cell development and neurodevelopment (Muthukumarana et al., 2006; Nathan et al., 2008; Thompson et al., 2010), whereas MARCH10 has been implicated in activation of the NLRP3 inflammasomes (Iyengar et al., 2011; Yan et al., 2015). The subcellular localizations of certain MARCH proteins are dictated by their transmembrane domains and PDZ-binding motifs (Lin et al., 2019). The precise subcellular distributions of MARCH proteins are crucial for efficient recognition of their substrate proteins in specific cellular compartments, as well as for their specific functions in regulation of cellular processes. Expression of MARCH proteins Some of the MARCH proteins, such as MARCH6 and MARCH10, are widely expressed across various tissues (Hassink et al., 2005; Iyengar et al., 2011), whereas other MARCH proteins are expressed in more restricted tissues. MARCH1 is mostly found in secondary lymphoid tissues, while MARCH11 is predominantly present in the testis (Bartee et al., 2004; Morokuma et al., 2007). MARCH4 has a relatively narrow expression profile, it is mainly expressed in the brain (Bartee et al., 2004). MARCH1-3, 5, 7-9 are mostly expressed in immune cells, including B cells, T cells, macrophages, monocytes and dendritic cells (DCs) (Bourgeois-Daigneault and Thibodeau, 2012; De Gassart et al., 2008; Goto et al., 2003; Metcalfe et al., 2005; Ramalho-Santos et al., 2002; Su et al., 2002; Tada et al., 2015; Thibodeau et al., 2008; Yonashiro et al., 2006), implying their potential functions in immune regulation. Certain cellular stimulations can regulate expression of MARCH proteins. For example, MARCH1 is induced by IL-1β, TNF-α and TGF-β (Meng et al., 2016). Transcription of MARCH1 decreases as DC maturation, indicating that MARCH1 might play a role in regulating antigen presentation and DC maturation (Baravalle et al., 2011; De Angelis Rigotti et al., 2017; De Gassart et al., 2008; Thibodeau et al., 2008; Tze et al., 2011; Xie et al., 2019). MARCH9 is transcriptionally induced following activation of Toll-like receptor (TLR) 3 or 4 in human DCs (De Angelis Rigotti et al., 2017). Transcription of MARCH2 is increased in human immunodeficiency virus 1 (HIV-1) infected cells, and MARCH2-deficiency leads to higher HIV-1 infection rates in 293T and Jurkat cells, suggesting that MARCH2 has a specific inhibitory function against HIV-1 infection (Zhang et al., 2018). It has been shown that TLR8 agonists, LPS and IL-3 induce MARCH3 transcription in monocytes (Fatehchand et al., 2016; Feng et al., 2022). Interestingly, it has been shown that the levels of certain MARCH proteins are elevated in cancers, such as MARCH1 in human hepatocellular carcinoma (HCC) cells (Xie et al., 2019), MARCH5 in ovarian cancer tissues (Hu et al., 2017), and MARCH8 in esophageal tumors (Singh et al., 2017). These observations suggest that these MARCH proteins may play a role in tumorigenesis. Roles of the MARCH proteins in cellular processes and diseases The MARCH1/8 subfamily MARCH1 is mainly found in antigen-presenting cells (APCs) and regulates the expression, trafficking, and degradation of various immune receptors by catalyzing the ubiquitination of its substrate proteins (Liu et al., 2022b). One of the critical functions of MARCH1 is to inhibit the expression of MHC II molecules. By mediating K11- and K63-linked polyubiquitination and lysosomal degradation of MHC class II molecules, MARCH1 can promote the internalization of MHC-II, which indirectly affects antigen recognition by CD4 T cells (Kozono et al., 2023; Liu et al., 2025a). MARCH1 can also down-regulate expression of the costimulatory molecule CD86 through a similar mechanism, thereby being involved in the activation of T cells (Baravalle et al., 2011). In addition, MARCH1 is critically involved in regulation of differentiation and functional maintenance of regulatory T cells (Tregs) (Oh et al., 2013; Oh et al., 2016). MARCH1-deficiency impairs MHC-II ubiquitination, resulting in DCs being unable to provide sufficient signals to thymic cells to support Treg differentiation, thereby causing a significant decrease in Treg cell numbers and TCR diversity (Oh et al., 2018). In addition, Tregs secrete IL-10 to up-regulate MARCH1 expression in macrophages, thereby inhibiting the role of APCs and maintaining normal physiological activity (Mittal et al., 2015). In acute myeloid leukemia (AML), MARCH1 promotes the proliferation of AML cells and inhibits apoptosis and differentiation by promoting MYCT1 ubiquitination and degradation (Liu et al., 2025b). MARCH8, also called c-MIR (Goto et al., 2003), functions similarly to herpesvirus proteins MIR1 and MIR2 and shares similar substrate specificity (Goto et al., 2003). It has been shown that MARCH8 acts as a cellular restriction factor for various viruses, including HIV-1, Ebola virus (EBOV), influenza virus (IFV), vesicular stomatitis virus (VSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), among others (Tada et al., 2022; Yu et al., 2023), mostly by down-regulating the expression of viral envelope glycoproteins on the cell surface (Lun et al., 2021; Zhang et al., 2020). Studies have shown that MARCH8-mediated down-regulation of viral glycoproteins occurs through different mechanisms. For example, the antagonistic effects of MARCH8 on VSV-G depend on viral protein cytoplasmic tail, whereas its effects on SARS-CoV-2 S proteins and HIV-1 Env do not depend on viral protein cytoplasmic tail, suggesting that MARCH8 may exert antiviral effects through different mechanisms (Lotke et al., 2024; Lun et al., 2021). It has also been demonstrated that MARCH8 suppresses the antiviral innate immune response by mediating K63-linked polyubiquitination and lysosomal degradation of IFITM3 (Wei et al., 2025). MARCH8 can participate in immune regulation by down-regulating expression of CD86 and MHC-II (Kim et al., 2014). However, unlike MARCH1, MARCH8 primarily performs this function in non-hematopoietic cells such as AECs and TECs (von Rohrscheidt et al., 2016). In addition, MARCH8 can regulate immune responses by targeting receptors on T cells (Casu et al., 2023). For example, MARCH8 can mediate K27-linked polyubiquitination of IL-7Rα, resulting in its lysosomal degradation and negative regulation of IL-7-induced T cell homeostasis (Gao et al., 2024). MARCH8 plays a role in CD4 T cell production by regulating MHC-II levels on the surface of TECs (Zinser et al., 2019). MARCH8 is also involved in antibacterial immunity, playing a defensive role during infection by bacteria such as Salmonella through regulating the autophagy pathway (Bayer-Santos et al., 2016). MARCH8 has been shown to be involved in tumorigenesis. For example, MARCH8 can inhibit liver cancer by promoting SREBP1 down-regulation and regulating de novo fatty acid synthesis (Tu et al., 2025). MARCH8 plays a role in suppression of pancreatic cancer metastasis by targeting the degradation of Orai3 (Raju et al., 2025). In osteosarcoma, MARCH8 inhibits tumor progression by mediating the ubiquitination and proteasomal degradation of NSUN6 (He et al., 2025). Furthermore, MARCH8 suppresses the glycolytic process by mediating ubiquitination and degradation of HK-2, thereby functioning as a suppressor in esophageal squamous cell carcinoma (ESCC) (Huang et al., 2025). MARCH1 and MARCH8 as members of the same subfamily have similar structures, which may be responsible for their similar roles in immune regulation. However, it has been shown that MARCH1/8 have different expression profiles (Ishido and Kajikawa, 2019). Under physiological conditions in vivo, MARCH1 can regulate MHC-II/CD86 in professional APCs, whereas MARCH8 performs analogous functions in non-professional APCs (TECs, AECs), thereby enabling fine-tuned regulation across different immune microenvironments (Liu et al., 2016; Schriek et al., 2021). While both MARCH1 and MARCH8 can target HIV-1 envelope glycoprotein to inhibit its infectivity (Umthong et al., 2021; Zhang et al., 2019), only MARCH8 but not MARCH1 can effectively inhibit influenza A virus (IAV) infection (Villalón-Letelier et al., 2021). Additionally, it has been shown that both MARCH1 and MARCH8 are involved in tumor immunity by ubiquitinating CD98 (Ablack et al., 2015), though it is unclear whether they function redundantly or independently in this process. The MARCH2/3 subfamily As a molecule that has been more extensively studied within the MARCH family, MARCH2 has been shown to regulate autophagy, virus infection, inflammatory response, heart-related diseases, and tumorigenesis (Cao et al., 2008; Fang et al., 2026; Han et al., 2012; Li et al., 2026; Li et al., 2025b; Umthong et al., 2024; Xia et al., 2016). It has been shown that MARCH2 targets Golgi-localized CFTR for ubiquitination and lysosomal degradation, leading to a decrease in LC3B-II level and ultimately inhibiting the degradation of autophagic substrates (Xia et al., 2016). In colorectal cancer, MARCH2-deficiency activates ER stress and sensitizes cancer cells to etoposide and cisplatin treatment (Liu et al., 2023b). It has been shown that MARCH2 can promote migration, epithelial-mesenchymal transition (EMT) and proliferation of liver cancer cells (Ni et al., 2024), inhibits migration of breast cancer cells by degrading SNAIL (Ito et al., 2024), and promotes migration of lung cancer cells by mediating K63-linked polyubiquitination of ALK5 (Tae et al., 2025). MARCH2 has been shown to function as a host restriction factor for various viruses. MARCH2 exists in nascent HIV-1 virions and inhibits virus entry in a manner that does not depend on its RING-CH domain (Umthong et al., 2024). MARCH2 inhibits the infectivity of EBOV by retaining the viral glycoprotein in the trans-Golgi network, thereby reducing its display on the cell surface (Yu et al., 2024). MARCH1/2 collaborate to trap the viral cell-to-cell fusion complex in the trans-Golgi network, thereby regulating the infection of pseudorabies virus (PRV) (Huang et al., 2024). MARCH2 can directly bind to GP85 of avian leukosis virus (ALV), mediate its K27-linked polyubiquitination and degradation via the proteasomal pathway, thereby inhibiting viral infection (Chen et al., 2025b). However, MARCH2 also can interact with PBLD and mediate its K27-linked polyubiquitination and lysosomal degradation, thereby promoting virus replication (Hou et al., 2026). Additionally, studies have shown that MARCH2 promotes K48-linked polyubiquitination and proteasomal degradation of NEMO, acting as a negative regulator in the NEMO signaling pathway (Chathuranga et al., 2020). MARCH2 has been demonstrated to have a significant regulatory function in inflammatory response. MARCH2 mediates K48-linked polyubiquitination and proteasomal degradation of VE-cadherin, resulting in disruption of the endothelial barrier (Fang et al., 2026). MARCH2 mediates the polyubiquitination and degradation of FASN, thereby protecting against hepatic lipid accumulation (Ni et al., 2025). A recent study shows that MARCH2 is associated with TNF-R1, resulting in K27-linked polyubiquitination of and its proteasomal degradation, thereby exacerbating TNF-induced acute liver injury (Li et al., 2026). Additionally, studies have shown that MARCH2 promotes K27-linked polyubiquitination and lysosomal degradation of PTPRD, which negatively regulates odontoblast differentiation (Feng et al., 2026). MARCH2 has been demonstrated to have a significant regulatory function in heart-related diseases. For example, MARCH2 promotes K48-linked polyubiquitination and proteasomal degradation of PGAM5, leading to a reduction in co-condensation of PGAM5 and MAVS, and subsequent suppression of activation of the NLRP3 inflammasome and pyroptosis in heart cells (Liu et al., 2024b). MARCH2 also alleviates aortic aneurysm/dissection by interacting with PKM2 to enhance its K33-linked polyubiquitination (Li et al., 2025b). MARCH2 can prevent doxorubicin-induced cardiomyopathy by promoting K27-linked polyubiquitination of NR1H2 to enhance its stability and promoting the clearance of apoptotic cardiomyocytes (Liu et al., 2026). As a member of the same subfamily as MARCH2, MARCH3 is similarly involved in tumorigenesis, inflammatory response, viral infection, and heart-related diseases. It has been shown that MARCH3 promotes K48-linked polyubiquitination and lysosomal degradation of the IL-6 receptor and gp130 to negatively regulate colitis-associated tumorigenesis (Lin et al., 2021). MARCH3 negatively regulates IL-1β- and IL-3-triggered inflammatory responses by promoting K48-linked polyubiquitination and the subsequent degradation of IL-1RI and IL-3Rα respectively (Feng et al., 2022; Lin et al., 2018). It has been shown that MARCH3 regulates endothelial cell barrier integrity by sustaining the activation of FoxO1 (Leclair et al., 2016). MARCH3 can enhance osteogenic differentiation of vascular smooth muscle cells through the activation of the JAK2/STAT5 signaling pathway (Chen et al., 2026). MARCH2 and MARCH3 belong to the same subfamily and have the highest sequence homology within the MARCH family. Unlike MARCH1 and MARCH8, which function mostly in a tissue-specific manner, MARCH2 and MARCH3 can play redundant roles in various physiological and pathological processes. For example, MARCH2 and MARCH3 target IL-5Rα for K27-linked polyubiquitination and lysosomal degradation, leading to suppression of eosinophilic airway inflammation in a redundant manner (Zeng et al., 2022). MARCH2 and MARCH3 redundantly target TIM-1, a Zika virus entry receptor, for K48-linked polyubiquitination and proteasomal degradation, resulting in negative regulation of Zika virus infection (Zhang et al., 2025). The MARCH4/9 subfamily MARCH4 has been implicated in promoting endocytosis of specific immune-related molecules, such as MHC-I and CD4, from the plasma membrane and directing them to lysosomes for degradation (Bartee et al., 2004). It has also been shown that MARCH4 regulates IL-6-triggered inflammatory response by down-regulating the level of IL-6Rα (Babon et al., 2019; Sandow et al., 2021). Several studies have suggested a potential role of MARCH4 in regulation of tumorigenesis. It has been demonstrated that low expression of MARCH4 is associated with poor prognostic outcomes in glioma patients (Li et al., 2022). A study has identified that MARCH4 can inhibit the progression of pancreatic cancer (Kong et al., 2026). Notably, EREG can up-regulate MARCH4 expression in cancer cells in a paracrine manner, thereby promoting malignant tumor progression (Wang et al., 2022). Additionally, MARCH4 has been shown to negatively regulate the progression of pancreatic cancer by mediating K6- and K63-linked mixed polyubiquitination and degradation of PD-L1 (Kong et al., 2026). The known substrates targeted by MARCH9 include MHC-I, CD4, and ICAM-1 (De Angelis Rigotti et al., 2017; Shen et al., 2018; Tan et al., 2019a). By mediating polyubiquitination and degradation of these substrates, MARCH9 plays an important regulatory role in antigen presentation and activation of T cells (De Angelis Rigotti et al., 2017). In acute pancreatitis, MARCH9 alleviates pancreatic injury by mediating the ubiquitination and degradation of NOX2, thus reducing the activation of NLRP3 inflammasomes (Lin et al., 2023, Lin et al., 2025). Recent studies also show that MARCH9 mediates K48-linked polyubiquitination and proteasomal degradation of NLRP3, leading to alleviated myocardial injury (Lu et al., 2025a). These studies suggest that the MARCH9-NLRP3 axis serves as a potential therapeutic target for acute pancreatitis and myocardial injury. MARCH9 is also implicated in regulation of tumorigenesis. For example, MARCH9 is highly expressed in colorectal cancer and is correlated with tumor metastasis and survival. Further studies suggest that MARCH9 promotes colorectal carcinogenesis by down-regulating CYLD and activating p65 (Liu et al., 2022a). MARCH9 regulates mitochondrial function by mediating K63-linked polyubiquitination of MFN2, thereby promoting the growth of ovarian cancer (Wang et al., 2025). It has also been shown that MARCH9 targets ICAM-1 for degradation, thereby inhibiting the proliferation and migration of lung adenocarcinoma (Shen et al., 2018). A pan-cancer prognostic analysis suggests that MARCH9 is upregulated in kidney cancer, liver cancer, ovarian cancer, and endometrial cancer, indicating that it may act as an oncogene in these cancers (Cao et al., 2022; Liu, et al., 2022a). As members of the same subfamily, both MARCH4 and MARCH9 can mediate down-regulation of IL-6Rα (Babon et al., 2019) and Mult1 (Nice et al., 2010). However, whether they are functionally redundant in regulating of these substrates needs to be further investigated. MARCH5 MARCH5 is also known as MITOL, which catalyzes ubiquitination of its substrates through K48- and K63-linked ubiquitin chains (Shiiba et al., 2020). MARCH5 plays an important regulatory role in mitochondrial quality control and dynamics by targeting MFN1, MFN2, DRP1 and FIS1 (Nakamura et al., 2006; Xu et al., 2016). MARCH5 targets MFN2 for polyubiquitination and proteasomal degradation to inhibit mitochondrial fusion (Valentino et al., 2025). MARCH5 also inhibits mitochondrial fission by ubiquitinating and degrading MIEF2 (Wu et al., 2026). MARCH5 is also implicated in tumorigenesis. In breast cancer, high levels of MARCH5 are associated with tumor progression, metastasis, and poor survival (Tang et al., 2019). MARCH5 promotes autophagy by inducing ubiquitination and degradation of P53, thereby enhancing tumor cell proliferation, migration, and invasion in HCC (Cai et al., 2024). MARCH5 promotes occurrence of AML through interaction with MFN2 (Larrue et al., 2025). MARCH5 functions as an oncogene by inhibiting mitochondrial fusion in multiple myeloma (Valentino et al., 2025). In colorectal cancer, the interaction between MARCH5 and PCDH17 inhibits the ubiquitination and degradation of VEGFR2, leading to increased vascular permeability and tumor metastasis (Dong et al., 2025). A study in prostate cancer has shown that therapies enhancing MARCH5-mediated MCL1 degradation increase the apoptotic response to BH3 mimetic drugs targeting BCL-XL, thereby providing a potential strategy for treating solid tumors (Arai et al., 2020). A recent study has shown that PD-1 signaling induces MARCH5, which in turn mediates K27-linked polyubiquitination and lysosomal degradation of the common cytokine receptor γ chain, thereby suppressing anti-tumor immunity (Liu et al., 2024a; Liu et al., 2023a). MARCH5 has also been implicated in positive regulation of NLRP3 inflammasomes by targeting NLRP3 for K27-linked polyubiquitination (Park et al., 2023). MARCH5 can positively regulate TLR7-mediated NF-κB activation by promoting K63-linked polyubiquitination of TANK (Shi et al., 2011). MARCH5 can also enhance Japanese encephalitis virus (JEV) infection by facilitating K27-linked polyubiquitination of the viral E protein (Li et al., 2025a). In the late phase of viral infection, MARCH5 catalyzes K48-linked polyubiquitination and degradation of VISA/MAVS, leading to attenuated innate immune response at the late phase of infection (Yan et al., 2017). MARCH5 can work together with Parkin and Mul1 to maintain mitochondrial homeostasis, thereby regulating Alzheimer's disease (AD) and Parkinson's disease (PD) (Covill-Cooke et al., 2018; Koyano et al., 2019). A recent study has also demonstrated that MARCH5 regulates mouse pancreatic islet β-cell function by mediating the degradation of TRIM28, thereby playing an important role in diabetes (Chen et al., 2025a). MARCH6 MARCH6 (also known as Doa10 or TEB4) is the mammalian homolog of yeast Doa10 (Wu et al., 2024). MARCH6 has transmembrane domains that form lipid-binding channels, and its E3 ligase activity is coupled with channel gating, allowing it to sense and respond to metabolic signals (Wu et al., 2024). MARCH6 is involved in regulating ER-associated protein degradation (ERAD) and various metabolic pathways (Botsch et al., 2024; Mehrtash and Hochstrasser, 2022). MARCH6 negatively regulates cholesterol synthesis and lipoprotein uptake by promoting ubiquitination and degradation of SQLE and HMGCR (Zelcer et al., 2014). MARCH6 also facilitates lysosomal degradation of LDLR by up-regulating IDOL (Loregger et al., 2016). Through these processes, MARCH6 contributes to fine regulation of cholesterol levels in the body (Loregger et al., 2016). In endothelial cells, MARCH6 maintains cholesterol homeostasis by regulating SQLE, thereby maintaining barrier integrity and angiogenic capacity (Tan et al., 2019b). MARCH6 participates in thyroid hormone production by degrading DIO2 (Zavacki et al., 2009). In HCC, MARCH6 promotes proliferation and migration of cancer cells by up-regulating ATF2 (Sun et al., 2021). In papillary thyroid carcinoma (PTC), MARCH6 promotes proliferation and migration of cancer cells by degrading DHX9 (Liu et al., 2021). MARCH6 inhibits ER stress by degrading FAM134B, which promotes carcinogenesis of glioma (Zhou et al., 2026). Expression of MARCH6 is positively correlated with androgen receptors and is co-regulated by Sp1 in prostate cancer, suggesting that cholesterol metabolism is related to prostate carcinogenesis (Coates et al., 2019). MARCH6 has also been shown to target TLR2 for degradation, which impairs the phagocytic function of macrophages and promotes the occurrence of ovarian cancer (Wu et al., 2025). MARCH6 has also been implicated in the regulation of cell death and organ damage. In a hypertensive cardiac remodeling model, MARCH6 inhibits cardiomyocyte ferroptosis by ubiquitinating ACSL4 and mediating its degradation (Hao et al., 2025). In acute kidney injury (AKI), MARCH6 suppresses ferroptosis in renal tubular epithelial cells by mediating the degradation of P53 and ACSL4, thereby alleviating kidney damage (Feng et al., 2025). MARCH7 MARCH7, also known as Axotrophin, is an atypical MARCH family member, which does not contain a transmembrane domain (Lin et al., 2019; Szigyarto et al., 2010). It has been shown that MARCH7 targets NLRP3 for K48-linked polyubiquitination and autophagic degradation, leading to inhibition of NLRP3 inflammasome activation and inflammatory response (Cai et al., 2022; Yan et al., 2015). MARCH7 can negatively regulate T cell activation by modulating expression of LIFR (Thompson et al., 2010). It has also been shown that MARCH7 interacts with FOXP3 to regulate transplant tolerance (Muthukumarana et al., 2006). MARCH7 is also implicated in tumorigenesis. In epithelial ovarian cancer, MARCH7 promotes tumor cell proliferation and migration by regulating the expression of E-cadherin/β-catenin (Zhang et al., 2016). In non-small cell lung cancer (NSCLC), high expression of MARCH7 is associated with tumorigenesis by dual regulation of the Wnt/β-catenin and NF-κB signaling pathways (Lu et al., 2025b). In esophageal cancer (EC), MARCH7 acts as an oncogene and promotes tumor progression by regulating E-cadherin (Singh et al., 2022). MARCH7 regulates migration of EC cells via a pathway mediated by Snail (Liu et al., 2019). MARCH7 inhibits occurrence and development of bladder cancer by targeting NOD1 for polyubiquitination and proteasomal degradation (Zhuang et al., 2024). MARCH7 has been shown to negatively regulate the autophagic process by mediating K6-, K11-, and K63-linked mixed polyubiquitination of ATG14 (Shi et al., 2023; Zhu et al., 2024). In non-alcoholic fatty liver disease (NAFLD), MARCH7 plays a protective role by regulating proteasomal degradation of NLRP3 (Chen et al., 2023). It has been shown that MARCH7 is highly expressed during spermatogenesis in rats, participating in its morphogenesis and functional maintenance (Zhao et al., 2013). MARCH7 has also been shown to be involved in development of neurons (Nathan et al., 2008). A recent study has demonstrated that MARCH7 is a dual-functional ferroptosis suppressor. On one hand, MARCH7 mediates K48-linked polyubiquitination and proteasomal degradation of NCOA4, thereby reducing the labile iron pool. On the other hand, MARCH7 mediates K63-linked polyubiquitination of TFR1, restricting its transport to the plasma membrane, thereby inhibiting cellular iron uptake (Huang et al., 2026). MARCH10 MARCH10 encodes two isoforms: the long one, MARCH10a, which contains a RING finger domain, and the short one, MARCH10b, which does not contain a RING finger domain (Iyengar et al., 2011). MARCH10 negatively regulates IAV infection by mediating K6-, K27-, and K29-linked mixed polyubiquitination of HA and its subsequent degradation via the lysosomal pathway (Tsai et al., 2025). Down-regulation of MARCH10 levels leads to higher IL-1β cytokine expression in differentiated human bronchial epithelial cells, suggesting that MARCH10 plays a protective role in innate immunity (Tsai et al., 2023). MARCH10 is highly expressed in testicular tissues, which MARCH10 regulates the polyubiquitination of flagellar microtubule proteins to maintain flagellar formation and structural integrity in spermatogenesis (Iyengar et al., 2011). MARCH10 is differentially expressed in various cancers, although its specific functions in tumorigenesis are still unclear (Behera et al., 2024). One study showed that MARCH10 expression level in HCC is related to prognosis and pathological features (Cao et al., 2022). MARCH11 MARCH11 is highly expressed during sperm development (Morokuma et al., 2007) and plays a role in in sperm formation by enhancing SAMT ubiquitination and lysosomal degradation (Yogo et al., 2012). MARCH11 may regulate intracellular transport processes by interacting with Veli (Morokuma et al., 2007). Recently, it has been shown that MARCH11 suppresses neuroblastoma cell growth by targeting the degradation of SLC3A2 (Lai et al., 2024), indicating that MARCH11 acts as a tumor suppressor gene in neuroblastoma. In addition, MARCH11 has been identified as a candidate marker for NSCLC (Ooki et al., 2017). Conclusions and perspectives Most of the MARCH family members contain transmembrane domains and are located on the plasma and/or organelle membrane. Several of the MARCH proteins are highly expressed in immune cells, positioning them to effectively regulate immune receptors and membrane proteins. Certain MARCH proteins are involved in the regulation of diverse substrates, including viral proteins, metabolic proteins, and organellar membrane proteins, in diverse cell types, suggesting that MARCH proteins are regulators of various cellular processes and functions (Table 1). Table 1MARCH family proteins in cellular processes and diseases.Table 1MARCHExpressionTargetsEffects on targetsFunctions/DiseasesReferencesMARCH1 (RNF171)Secondary lymphoidMHC-IIK63- and K11-linked polyubiquitination, lysosomal degradationInhibits recognition of antigens by CD4 T cells(Kozono et al., 2023; Liu et al., 2025a)B cellCD86Polyubiquitination, degradationInhibits T cell activationBaravalle et al. (2011)MonocyteHIV-1 envelope glycoproteinDown-regulationInhibits HIV-1 infection(Umthong et al., 2021; Zhang et al., 2019)Immature DCCD98Polyubiquitination, lysosomal degradationInhibits T cell proliferationAblack et al. (2015)MYCT1Polyubiquitination, degradationPromotes proliferation of AML cellsLiu et al. (2025b)MARCH2 (RNF172)UbiquitousCFTRPolyubiquitination, lysosomal degradationInhibits degradation of autophagic substratesXia et al. (2016)SNAILDown-regulationInhibits migration of breast cancer cellsIto et al. (2024)ALK5K63-linked polyubiquitinationPromotes migration of lung cancer cellsTae et al. (2025)GP85K27-linked polyubiquitination, proteasomal degradationInhibits ALV infectionChen et al. (2025b)NEMOK48-linked polyubiquitination, proteasomal degradationMaintains innate immune homeostasisChathuranga et al. (2020)PGAM5K48-linked polyubiquitination, proteasomal degradationInhibits NLRP3 inflammasome/cardiomyocyte pyroptosisLiu et al. (2024b)PKM2K33-linked polyubiquitinationAlleviates aortic aneurysm/dissectionLi et al. (2025b)NR1H2K27-linked polyubiquitinationPromotes clearance of apoptotic cardiomyocytesLiu et al. (2026)IL-5RαK27-linked polyubiquitination, lysosomal degradationInhibits eosinophilic airway inflammationZeng et al. (2022)TIM-1K48-linked polyubiquitination, proteasomal degradationInhibits Zika virus infectionZhang et al. (2025)PBLDK27-linked polyubiquitination, lysosomal degradationPromotes virus replicationHou et al. (2026)VE-cadherinK48-linked polyubiquitination, proteasomal degradationCauses endothelial barrier disruptionFang et al. (2026)FASNPolyubiquitination, degradationInhibits hepatic lipid accumulationNi et al. (2025)TNF-R1K27-linked polyubiquitination, proteasomal degradationPromotes progression of acute liver injuryLi et al. (2026)PTPRDK27-linked polyubiquitination, lysosomal degradationInhibits odontoblast differentiationFeng et al. (2026)MARCH3 (RNF173)UbiquitousIL-6RαK48-linked polyubiquitination, lysosomal degradationInhibits colitis-associated cancerLin et al. (2021)gp130K48-linked polyubiquitination, lysosomal degradationInhibits colitis-associated cancerLin et al. (2021)IL-1RIK48-linked polyubiquitination, lysosomal degradationAttenuates IL-1β-triggered inflammatory responseLin et al. (2018)IL-3RαK48-linked polyubiquitination, proteasomal degradationAttenuates IL-3-triggered physiological functionsFeng et al. (2022)FoxO1ActivationRegulates endothelial cell barrier integrityLeclair et al. (2016)IL-5RαK27-linked polyubiquitination, lysosomal degradationInhibits eosinophilic airway inflammationZeng et al. (2022)TIM-1K48-linked polyubiquitination, proteasomal degradationInhibits Zika virus infectionZhang et al. (2025)MARCH4 (RNF174)LungIL-6RαDown-regulationInhibits IL6-triggered inflammatory response(Babon et al., 2019; Sandow et al., 2021)BrainPD-L1K6- and K63-linked mixed polyubiquitination, degradationInhibits progression of pancreatic cancerKong et al. (2026)PlaxentaMARCH5 (RNF153, MITOL)UbiquitousMFN2Polyubiquitination, proteasomal degradationInhibits mitochondrial fusionValentino et al. (2025)P53Polyubiquitination, degradationPromotes HCC cells proliferation and migrationCai et al. (2024)VEGFR2Polyubiquitination, degradationInhibits vascular permeability and colorectal cancer metastasisDong et al. (2025)MCL1Down-regulationPromotes apoptotic response to BH3 mimetic, inhibits prostate cancerArai et al. (2020)γ chainK27-linked polyubiquitination, lysosomal degradationInhibits anti-tumor immunity(Liu et al., 2024a; Liu et al., 2023a)NLRP3K27-linked polyubiquitinationPromotes NLRP3 inflammasome activationPark et al. (2023)TANKK63-linked polyubiquitinationPromotes TLR7-mediated NF-κB activationShi et al. (2011)VISA/MAVSK48-linked polyubiquitination, degradationInhibits type I interferon responseYan et al. (2017)TRIM28Down-regulationPromotes insulin production and glucose toleranceChen et al. (2025a)MIEF2Polyubiquitination, degradationInhibits mitochondrial fissionWu et al. (2026)E proteinK27-linked polyubiquitinationPromotes JEV infectionLi et al. (2025a)MARCH6 (RNF176, TEB4, Doa10)UbiquitousSQLEPolyubiquitination, degradationInhibits cholesterol synthesis and lipoprotein uptake(Zelcer et al., 2014; Tan et al., 2019b)HMGCRPolyubiquitination, degradationInhibits cholesterol synthesis and lipoprotein uptakeZelcer et al. (2014)IDOLUp-regulationPromotes LDLR lysosomal degradationLoregger et al. (2016)DIO2Down-regulationInhibits thyroid hormone productionZavacki et al. (2009)ATF2Up-regulationPromotes HCC cells proliferation and migrationSun et al. (2021)DHX9Down-regulationPromotes PTC cells proliferation and migrationLiu et al. (2021)FAM134BDown-regulationInhibits ER stressZhou et al. (2026)ACSL4Polyubiquitination, degradationInhibits cardiomyocyte and renal tubular epithelial cells ferroptosis(Feng et al., 2025; Hao et al., 2025)P53Down-regulationInhibits renal tubular epithelial cells ferroptosisFeng et al. (2025)TLR2Down-regulationInhibits phagocytic function of macrophagesWu et al. (2025)MARCH7 (RNF177, AXOT)UbiquitousNLRP3K48-linked polyubiquitination, autophagic degradationInhibits NLRP3 inflammasome and inflammatory response(Cai et al., 2022; Yan et al., 2015)LIFRDown-regulationInhibits T cell activationThompson et al. (2010)E-cadherinDown-regulationPromotes progression of epithelial ovarian cancer and esophageal cancer(Singh et al., 2022; Zhang et al., 2016)β-cateninUp-regulationPromotes progression of epithelial ovarian cancerZhang et al. (2016)NOD1Polyubiquitination, proteasomal degradationInhibits occurrence and development of bladder cancerZhuang et al. (2024)ATG14K6-, K11-, and K63-linked mixed polyubiquitinationInhibits autophagic process(Shi et al., 2023; Zhu et al., 2024)NLRP3Proteasomal degradationAlleviates NAFLDChen et al. (2023)NCOA4K48-linked polyubiquitination, proteasomal degradationReduces the labile iron poolHuang et al. (2026)TFR1K63-linked polyubiquitinationInhibits cellular iron uptakeHuang et al. (2026)MARCH8 (RNF178, c-MIR)UbiquitousIL-7RαK27-linked polyubiquitination, lysosomal degradationInhibits IL-7-induced T cell homeostasisGao et al. (2024)MHC-IIUp-regulationPromotes production of CD4 T cellsZinser et al. (2019)HIV-1 envelope glycoproteinDown-regulationInhibits HIV-1 infection(Umthong et al., 2021; Zhang et al., 2019)CD98Polyubiquitination, lysosomal degradationInhibits T cell proliferationAblack et al. (2015)IFITM3K63-linked polyubiquitination, lysosomal degradationInhibits antiviral innate immune responsesWei et al. (2025)SREBP1Down-regulationInhibits liver cancerTu et al. (2025)Orai3Down-regulationInhibits pancreatic cancer metastasisRaju et al. (2025)NSUN6Polyubiquitination, proteasomal degradationInhibits osteosarcoma progressionHe et al. (2025)HK-2Polyubiquitination, degradationInhibits ESCC progressionHuang et al. (2025)MARCH9 (RNF179)LungNOX2Polyubiquitination, degradationInhibits NLRP3 inflammasome activation(Lin et al., 2023; Lin et al., 2025)Lymph nodeNLRP3K48-linked polyubiquitination, proteasomal degradationAlleviates myocardial injuryLu et al. (2025a)SpleenCYLDDown-regulationPromotes progression of colorectal cancerLiu et al. (2022a)T cell, B cell, DCICAM-1Down-regulationInhibits proliferation and migration of lung adenocarcinomaShen et al. (2018)MFN2K63-linked polyubiquitinationPromotes growth of ovarian cancerWang et al. (2025)MARCH10 (RNF190)UbiquitousHAK6-, K27-, and K29-linked mixed polyubiquitination, lysosomal degradationInhibits IAV infectionTsai et al. (2025)MARCH11 (RNF226)TestisSAMTPolyubiquitination, lysosomal degradationInvolves in sperm formationYogo et al. (2012)VeliInteractionRegulates intracellular transport processesMorokuma et al. (2007)SLC3A2Down-regulationInhibits neuroblastoma cells growthLai et al. (2024) MARCH family proteins in cellular processes and diseases. Despite significant advancements in understanding the roles and mechanisms of MARCH proteins, many outstanding questions remain. For example, 1) What other substrates are targeted by MARCH proteins? Systemic proteomics analysis with tissues derived from MARCH single or double knockout mice may particularly answer this question in the future. 2) How is the substrate specificity of MARCH proteins achieved? Currently, there are no structural studies on MARCH-substrate complex, which is needed to answer this question in the future. 3) How are the protein level and activity of MARCH proteins regulated? Although transcriptional induction of certain MARCH proteins is identified, a study has shown that TYRO3-mediated phosphorylation maintains MARCH3 in an inactive state in unstimulated cells. Upon IL-1β stimulation, CDC25A dephosphorylates and activates MARCH3, leading to K48-linked polyubiquitination and degradation of IL-1RI and subsequent inhibition of IL-1RI-mediated signaling (Lin et al., 2018), whether MARCH proteins are regulated by other post-translational modifications, ligand-induced conformation changes, subcellular trafficking and other types of mechanisms is mostly unknown. 4) How does deregulation of MARCH proteins cause diseases? Can MARCH proteins be targeted for development of drugs for treatment of related diseases? Answering these outstanding questions would enhance our understanding of the functions and mechanisms of MARCH proteins in both physiological and pathological contexts, as well as to develop targeted drugs for treatment of serious human diseases. As therapeutic strategies continue to advance, approaches such as small-molecule inhibitors targeting E3 ubiquitin ligases and PROTAC-based targeted protein degradation may facilitate the development of therapies directed against MARCH proteins, ultimately offering potential clinical benefits to patients. CRediT authorship contribution statement Qi Zhang: Writing – original draft, Formal analysis, Conceptualization. Yu-Ting Qiao: Writing – original draft. Shu Li: Writing – review & editing, Supervision, Funding acquisition, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements This work was supported by grants from the State Key R&D Program of China (2024YFA1306500, 2022YFA1304900), the National Natural Science Foundation of China (32188101), the Major Project of Guangzhou National Laboratory (GZNL2024A01014, GZNL2024A01016), the Fundamental Research Funds for the Central Universities (2042022dx0003), and Natural Science Foundation of Wuhan (2024040701010031). References